NLNina S. Los

Nina S. Los

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina S. Los has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ellagic acid from Terminalia leiocarpa downregulates estrogen-dependent signaling and epithelial-to-mesenchymal transition canonical pathways in MCF-7 cells

    by Temitope O. Lawal, Pinal N. Kanabar, Nina S. Los, Shitalben M. Patel, Mark Maienschein-Cline, Zarema H. Arbieva, Bolanle A. Adeniyi, Gail B. Mahady

    Breast cancer remains the most diagnosed cancer among women worldwide, and its prevalence continues to increase annually. Previously, we reported that ellagic acid (EA), a compound isolated from Terminalia leiocarpa (DC.) Baill., a plant used in Nigerian traditional medicine, inhibited the proliferation of cultured human MCF-7 breast cancer cells. EA is a pharmacologically active polyphenolic compound with antioxidant, anti-inflammatory, and anti-estrogenic activities. In this work, we investigated the effects of EA on the transcriptome of MCF-7 cells using next-generation sequencing. After EA treatment, MCF-7 cells were harvested, and total RNA was isolated and used to prepare RNA sequencing libraries. Sequencing was performed using NovaSeq 6000. The results showed that EA significantly altered gene expression patterns in MCF-7 cells. Bioinformatic analysis of the sequencing data revealed that 4,848 transcripts were differentially expressed, with 2,180 upregulated genes and 2,668 downregulated genes (q ≤ 0.01). Ingenuity Pathway Analysis indicated that EA-induced expression changes mapped to 98 canonical pathways, including upregulation of apoptosis signaling pathways and downregulation of estrogen signaling and estrogen-dependent breast cancer signaling pathways (q ≤ 0.05). Furthermore, EA downregulated gene expression in the epithelial-to-mesenchymal transition (EMT) canonical pathway, such as PRRX1/2, TGF, TWIST1, and VIM. These data indicate that EA has multiple mechanisms of action in MCF-7 cells, including the induction of apoptosis and the reduction of both estrogen and EMT signaling. Thus, with further research, EA may serve as an inexpensive, safe, and effective treatment for breast cancer and metastatic diseases.

  • Open Access

    RNA-Seq Analysis of MCF-7 Breast Cancer Cells Treated with Methyl Gallate Isolated from the Rhizomes of Nymphaea Odorata L. Shows Upregulation of Apoptosis, Autophagy, and Unfolded Protein Canonical Pathways

    by Nishikant A. Raut, Pinal N. Kanabar, Mark Maienschein-Cline, Nina S. Los, Zarema Arbieva, Temitope O. Lawal, Shitalben Patel, Gail B. Mahady

    The effects of a methanol extract of Nymphaea odorata (MeNO) rhizomes, its fractions and the active compound (methyl gallate, MeG) were investigated in estrogen receptor-positive (ER+) breast cancer cell lines MCF-7 and T47-D:A18, as well as ER-negative line SKBr3. Cell viability and cytotoxicity were determined using CellTiter-Glo® 2.0 assays at concentrations ranging from 1 to 100 μg/mL. Caspase activity and apoptosis were determined using Caspase-Glo® 3/7, Caspase-Glo® 8, and ApoTox-Glo™ triplex assays, as well as qPCR. Total RNA was isolated from MCF-7 cells treated with MeG. RNA-seq libraries were prepared using a Universal Plus mRNASeq kit, and sequencing was performed on a NovaSeq 6000. MeNO inhibited the growth of MCF-7 cells with an IC50 of 14.1 μg/mL, as well as T47-D:A18 (IC50 of 25.6 μg/mL) and SKBr3 cells (IC50 of 35.5 μg/mL). Bioassay-guided fractionation of MeNO in MCF-7 cells identified the active fraction containing one compound, namely methyl gallate (MeG). MeG had an IC50 of 8.6 μg/mL in MCF-7 cells. Transcriptomic analysis of MeG-treated MCF-7 cells showed differential expression of 10,634 genes, with 5643 upregulated and 4991 downregulated (FDR < 0.05). Ingenuity pathway analysis revealed the involvement of 43 canonical pathways, with the top upregulated pathways including apoptosis, autophagy, and the unfolded protein response pathways.


  • Open Access

    Peonidin-3-O-glucoside and Resveratrol Increase the Viability of Cultured Human hFOB Osteoblasts and Alter the Expression of Genes Associated with Apoptosis, Osteoblast Differentiation and Osteoclastogenesis

    by Keila C. Ostos Mendoza, Karen D. Garay Buenrostro, Pinal N. Kanabar, Mark Maienschein-Cline, Nina S. Los, Zarema Arbieva, Nishikant A. Raut, Temitope O. Lawal, Alice M. López, Paulina Cabada-Aguirre, et al.

    High-throughput RNA-sequencing can determine the impact of nutrients and their combinations on gene transcription levels in osteocytes, and clarify the biological pathways associated with their impact on bone tissues. Previously, we reported that resveratrol (RES) and peonidin-3-O-glucoside (POG) increased osteoblastogenesis, as well as reduced osteoclastogenesis in transgenic teleost fish models. Here, we perform whole-genome transcriptomic profiling of osteoblasts treated with POG or RES to provide a comprehensive understanding of alterations in gene expression and the molecular mechanisms involved. Cultured human fetal osteoblastic hFOB 1.19 cells were treated with the test compounds, and then RNA was used to prepare RNA-seq libraries, that were sequenced using a NovaSeq 6000. Treatment with POG or RES increased osteoblast proliferation and reduced apoptosis. Transcriptomic profiling showed that of the 29,762 genes investigated, 3177 were differentially expressed (1481 upregulated, 1696 downregulated, FDR ≤ 0.05) in POG-treated osteoblasts. In the RES-treated osteoblasts, 2288 genes were differentially expressed (DGEs, 1068 upregulated, 1220 downregulated, FDR ≤ 0.05). Ingenuity® Pathway Analysis (IPA) of DGEs from RES or POG-treated osteoblasts revealed significant downregulation of the apoptosis, osteoarthritis and HIF1α canonical pathways, and a significant reduction in Rankl mRNA expression. The data suggest that RES and POG have both anabolic and anticlastogenic effects.